Literature DB >> 21913045

A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer.

Jerome Martin Laurence1, Peter Duy Tran, Kavita Morarji, Guy D Eslick, Vincent Wai To Lam, Charbel Sandroussi.   

Abstract

INTRODUCTION: This systematic review and meta-analysis aims to characterize the surgically important benefits and complications associated with the use of neoadjuvant chemoradiotherapy for the treatment of both resectable and initially unresectable pancreatic cancer. Studies were identified through a systematic literature search and analyzed by two independent reviewers. Survival, peri-operative complications, death rate, pancreatic fistula rate, and the incidence of involved surgical margins were analyzed and subject to meta-analysis.
METHODS: Nineteen studies, involving 2,148 patients were identified. Only cohort studies were included.
RESULTS: The meta-analysis found that patients with unresectable pancreatic cancer who underwent neoadjuvant chemoradiotherapy achieved similar survival outcomes to patients with resectable disease, even though only 40% were ultimately resected. Neoadjuvant chemoradiotherapy was not associated with a statistically significant increase in the rate of pancreatic fistula formation or total complications.
CONCLUSION: Patients receiving neoadjuvant chemoradiotherapy were less likely to have a positive resection margin, although there was an increase in the risk of peri-operative death.

Entities:  

Mesh:

Year:  2011        PMID: 21913045     DOI: 10.1007/s11605-011-1659-7

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  37 in total

Review 1.  Pancreatic carcinoma deemed unresectable at exploration may be resected for cure: an institutional experience.

Authors:  C Chao; J P Hoffman; E A Ross; M H Torosian; B L Eisenberg
Journal:  Am Surg       Date:  2000-04       Impact factor: 0.688

2.  A comparison of methods to detect publication bias in meta-analysis.

Authors:  P Macaskill; S D Walter; L Irwig
Journal:  Stat Med       Date:  2001-02-28       Impact factor: 2.373

3.  Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement.

Authors:  Ross A Abrams; Andrew M Lowy; Eileen M O'Reilly; Robert A Wolff; Vincent J Picozzi; Peter W T Pisters
Journal:  Ann Surg Oncol       Date:  2009-04-24       Impact factor: 5.344

Review 4.  A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer.

Authors:  Alessio G Morganti; Mariangela Massaccesi; Giuseppe La Torre; Luciana Caravatta; Adele Piscopo; Rosa Tambaro; Luigi Sofo; Giuseppina Sallustio; Marcello Ingrosso; Gabriella Macchia; Francesco Deodato; Vincenzo Picardi; Edy Ippolito; Numa Cellini; Vincenzo Valentini
Journal:  Ann Surg Oncol       Date:  2009-10-24       Impact factor: 5.344

5.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

6.  A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database.

Authors:  May Piperdi; Theodore P McDade; Joon K Shim; Bilal Piperdi; Sidney P Kadish; Mary E Sullivan; Giles F Whalen; Jennifer F Tseng
Journal:  HPB (Oxford)       Date:  2010-04       Impact factor: 3.647

7.  Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas.

Authors:  J F Pingpank; J P Hoffman; E A Ross; H S Cooper; N J Meropol; G Freedman; W H Pinover; T E LeVoyer; A R Sasson; B L Eisenberg
Journal:  J Gastrointest Surg       Date:  2001 Mar-Apr       Impact factor: 3.452

8.  Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy.

Authors:  H Golcher; T Brunner; G Grabenbauer; S Merkel; T Papadopoulos; W Hohenberger; T Meyer
Journal:  Eur J Surg Oncol       Date:  2008-01-10       Impact factor: 4.424

9.  Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer?

Authors:  Hong Jin Kim; Karen Czischke; Murray F Brennan; Kevin C Conlon
Journal:  J Gastrointest Surg       Date:  2002 Sep-Oct       Impact factor: 3.452

10.  Practical methods for incorporating summary time-to-event data into meta-analysis.

Authors:  Jayne F Tierney; Lesley A Stewart; Davina Ghersi; Sarah Burdett; Matthew R Sydes
Journal:  Trials       Date:  2007-06-07       Impact factor: 2.279

View more
  35 in total

Review 1.  The role of neoadjuvant therapy in pancreatic cancer: a review.

Authors:  Suzanne Russo; John Ammori; Jennifer Eads; Jennifer Dorth
Journal:  Future Oncol       Date:  2016-02-01       Impact factor: 3.404

Review 2.  Borderline resectable pancreatic cancer.

Authors:  Bhargava Mullapudi; Patrick J Hawkes; Asish Patel; Chandrakanth Are; Subhasis Misra
Journal:  Indian J Surg Oncol       Date:  2015-01-04

3.  Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer.

Authors:  Masayuki Sho; Takahiro Akahori; Toshihiro Tanaka; Shoichi Kinoshita; Minako Nagai; Satoshi Nishiwada; Tetsuro Tamamoto; Hideyuki Nishiofuku; Chiho Ohbayashi; Masatoshi Hasegawa; Kimihiko Kichikawa; Yoshiyuki Nakajima
Journal:  Langenbecks Arch Surg       Date:  2015-05-01       Impact factor: 3.445

4.  Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality.

Authors:  Jason W Denbo; Morgan L Bruno; Jordan M Cloyd; Laura Prakash; Jeffrey E Lee; Michael Kim; Christopher H Crane; Eugene J Koay; Sunil Krishnan; Prajnan Das; Bruce D Minsky; Gauri Varadhachary; Rachna Shroff; Robert Wolff; Milind Javle; Michael J Overman; David Fogelman; Thomas A Aloia; Jean-Nicolas Vauthey; Jason B Fleming; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2016-10-11       Impact factor: 3.452

Review 5.  Update on the Management of Pancreatic Cancer in Older Adults.

Authors:  Shin Yin Lee; Moussa Sissoko; Kevan L Hartshorn
Journal:  Curr Oncol Rep       Date:  2016-10       Impact factor: 5.075

6.  Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma.

Authors:  Hideo Tomihara; Hidetoshi Eguchi; Daisaku Yamada; Kunihito Gotoh; Koichi Kawamoto; Hiroshi Wada; Tadafumi Asaoka; Takehiro Noda; Yutaka Takeda; Masahiro Tanemura; Masaki Mori; Yuichiro Doki
Journal:  Surg Today       Date:  2016-09-01       Impact factor: 2.549

7.  Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationships.

Authors:  Avani S Dholakia; Amy Hacker-Prietz; Aaron T Wild; Siva P Raman; Laura D Wood; Peng Huang; Daniel A Laheru; Lei Zheng; Ana De Jesus-Acosta; Dung T Le; Richard Schulick; Barish Edil; Susannah Ellsworth; Timothy M Pawlik; Christine A Iacobuzio-Donahue; Ralph H Hruban; John L Cameron; Elliot K Fishman; Christopher L Wolfgang; Joseph M Herman
Journal:  J Radiat Oncol       Date:  2013-09-22

Review 8.  Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents.

Authors:  Amanda J Walker; Sara R Alcorn; Amol K Narang; Katriana M Nugent; Aaron T Wild; Joseph M Herman; Phuoc T Tran
Journal:  Curr Probl Cancer       Date:  2013-10-05       Impact factor: 3.187

9.  Does the use of neoadjuvant therapy for pancreatic adenocarcinoma increase postoperative morbidity and mortality rates?

Authors:  Amanda B Cooper; Abhishek D Parmar; Taylor S Riall; Bruce L Hall; Matthew H G Katz; Thomas A Aloia; Henry A Pitt
Journal:  J Gastrointest Surg       Date:  2014-08-05       Impact factor: 3.452

Review 10.  Management options in locally advanced pancreatic cancer.

Authors:  Omar Y Mian; Ashwin N Ram; Richard Tuli; Joseph M Herman
Journal:  Curr Oncol Rep       Date:  2014-06       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.